CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Single-cell RNA Sequencing Contributes to the Treatment of Acute Myeloid Leukaemia With Hematopoietic Stem Cell Transplantation, Chemotherapy, and Immunotherapy.
Single-cell RNA Sequencing Contributes to the Treatment of Acute Myeloid Leukaemia With Hematopoietic Stem Cell Transplantation, Chemotherapy, and Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
急性髓系白血病(AML)由髓系原始细胞成熟和分化异常、转录及表观遗传改变以及凋亡受损所致,最终导致骨髓中恶性血细胞过度增殖。这些突变造成肿瘤异质性,与复发和死亡风险升高相关,也会降低造血干细胞移植(HSCT)、化疗及免疫疗法(免疫检查点抑制剂、CAR-T 细胞疗法和癌症疫苗等)的疗效。单细胞RNA测序(scRNA-seq)还可识别细胞亚克隆并描绘肿瘤特征,从而为改善AML管理发现新的诊断和治疗靶点。若能收集患者及供者干细胞的遗传和转录信息,HSCT流程可能更为顺利,从而节省时间并降低体内发生有害副作用的风险。
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations and impaired apoptosis, all of which lead to excessive proliferation of malignant blood cells in the bone marrow. It is these mutations that cause tumor heterogeneity, which is linked to a higher risk of relapse and death and makes anti-AML treatments like HSCT, chemotherapy, and immunotherapy (ICI, CAR T-cell-based therapies, and cancer vaccines) less effective.
Single-cell RNA sequencing (scRNA-seq) also makes it possible to find cellular subclones and profile tumors, which opens up new diagnostic and therapeutic targets for better AML management. The HSCT process works better when genetic and transcriptional information about the patient and donor stem cells is collected. This saves time and lowers the risk of harmful side effects happening in the body.
MEMBER ACCOUNT
登录成功会直接打开下一页。